Will Weinstein Appointed to Hansen Medical's Board of Directors
Company's Board Gains Valuable Wall Street Experience
MOUNTAIN VIEW, CA -- (Marketwired) -- 07/10/13 -- Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that Will K. Weinstein has been appointed as a Director,
effective as of July 8, 2013. The appointment increases the Company's
board membership to eight, seven of whom are independent. Mr.
Weinstein brings to the board over 40 years of experience in the
financial services industry.
"Will's extensive financial services expertise will be extremely
valuable for us as our EP and vascular businesses continue to grow,"
said Mike Eagle, Chairman of the Board for Hansen Medical. "We look
forward to leveraging his vast finance experience."
Currently, Mr. Weinstein serves as a Financial and Investment Advisor
and Money Manager to a number of individuals and corporations active
in the equity markets. He is also a limited partner of Conifer
Securities in San Francisco. Mr. Weinstein was a Governor of the
Midwest Stock Exchange for five years, and also served for five years
as a Governor of the American Stock Exchange until its merger with
NASDAQ in 1998. Mr. Weinstein was Chairman and CEO of Genesis
Merchant Group Securities in San Francisco from 1989 until it was
sold in 1997. He then started and managed a hedge fund and two
private equity partnerships. Prior to Genesis, he was the Investment
and Financial Policy Advisor to the Pritzker family in Chicago.
Previously, Mr. Weinstein was the Managing Partner of Montgomery
Securities in San Francisco and Chairman of its Investment Policy
Committee. He was also a member of the Executive Committee of
Oppenheimer and Co. and its partner in charge of trading in the
Mr. Weinstein is a member of the board of the Osher Center for
Integrative Medicine in San Francisco, and he recently joined the
board of the San Francisco State University Foundation, where he is a
member of the endowment committee. Mr. Weinstein's previous board
affiliations include DHL Incorporated, Butterfield & Butterfield,
Beverly Enterprises, Mt. Zion Hospital, the San Francisco Chapter of
the Juvenile Diabetes Research Foundation, the San Francisco
the Robert H. Lurie Comprehensive Cancer Center, the
UCSF Department of Prostate Cancer Advocacy Core and the City College
of San Francisco Foundation. He was a member of a former California
Controller's Advisory Council for Investment and served as the West
Coast Chair for Bridging the Rift Foundation.
Over the past several years, Mr. Weinstein has taught at many
universities throughout the United States and abroad. This summer
will be his tenth teaching "Integrity and Ethics in the Real World"
at the University of Hawaii at Manoa, a class co-sponsored by the
Richardson School of Law and the Shidler College of Business. In
addition, Mr. Weinstein had taught "Ethics in Decision Making" at the
Graduate Business School at San Francisco State University since
2006; before taking a leave over the last two years. Prior to his
duties at San Francisco State University, he co-taught a business
ethics class at San Francisco City College with the Dean of the
"Hansen Medical is at the forefront of innovation in intravascular
robotics," said Mr. Weinstein. "I am pleased to be joining the
Company at such an exciting time."
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global
leader in intravascular robotics, developing products and technology
designed to enable the accurate positioning, manipulation and control
of catheters and catheter-based technologies. The Company's
Magellan(TM) Robotic System, NorthStar(TM) Robotic Catheter and
related accessories, which are intended to facilitate navigation to
anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union, and the U.S. In the European Union,
the Company's Sensei(R) X Robotic Catheter System and Artisan Control
Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the U.S.
Food and Drug Administration for manipulation and control of certain
mapping catheters in EP procedures. In the United States, the Sensei
System is not approved for use in guiding ablation procedures; this
use remains experimental. The U.S. product labeling therefore
provides that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
This press release contains forward-looking statements regarding,
among other things, statements relating to goals, plans, objectives,
milestones and future events. All statements, other than statements
of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the words
"plan," "expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date of
this press release and are subject to risks, uncertainties, changes
in circumstances and other factors that may cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Examples of
such statements include statements about the anticipated growth in
Hansen Medical intravascular robotics technology for EP and vascular
applications. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements include, among others: engineering, regulatory,
manufacturing, sales and customer service challenges in developing
new products and entering new markets; the commercial viability of
our products in the electrophysiology and vascular markets; potential
safety and regulatory issues that could slow or suspend our sales;
the effect of economic conditions on capital spending by our
potential customers; the uncertain timelines for the sales cycle for
newly introduced products; the rate of adoption of our systems and
the rate of use of our catheters; the scope and validity of
intellectual property rights applicable to our products; competition
from other companies; our ability to recruit and retain key
personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2013 filed with the SEC on May 10,
2013 and the risks discussed in our other reports filed with the SEC.
Given these uncertainties, you should not place undue reliance on the
-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries.
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
FTI Consulting, Inc.
Press spacebar to pause and continue. Press esc to stop.